| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18826857 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 101 journal articles in the PubMed database | Email to a friend | | |
| Fadem1 SZ, Al-Saghir2 F, Zollner3 G, et al.
Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol – a dose equivalency and titration study. [JOURNAL ARTICLE]
Clin Nephrol 2008 Oct; Volume 70(October):319-324.
Abstract | Full Citation | Find Related Articles | | Zisman AL, Ghantous W, Schinleber P, et al.
Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. [Clinical Trial, Phase IV, Journal Article, Randomized Controlled Trial]
Am J Nephrol 2005 Nov-Dec; 25(6):591-5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Lindberg J, Martin KJ, González EA, et al.
A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. [Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study]
Clin Nephrol 2001 Oct; 56(4):315-23.
Abstract | Full Citation | Find Related Articles | | Martin KJ, González EA, Gellens M, et al.
19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Am Soc Nephrol 1998 Aug; 9(8):1427-32.
Abstract | Full Citation | Find Related Articles | | Greenbaum LA, Benador N, Goldstein SL, et al.
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. [Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
Am J Kidney Dis 2007 Jun; 49(6):814-23.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Llach F, Keshav G, Goldblat MV, et al.
Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
Am J Kidney Dis 1998 Oct; 32(2 Suppl 2):S48-54.
Abstract | Full Citation | Find Related Articles | | Ross EA, Tian J, Abboud H, et al.
Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis or Peritoneal Dialysis. [JOURNAL ARTICLE]
Am J Nephrol 2007 Oct 3; 28(1):97-106.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Staniforth ME, Cheng SC, Coyne DW
Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. [Journal Article]
Clin Nephrol 2005 Jun; 63(6):454-60.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Llach F, Yudd M
Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. [Journal Article, Multicenter Study]
Am J Kidney Dis 2001 Nov; 38(5 Suppl 5):S45-50.
Abstract | Full Citation | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
